November 1, 1995Expert Opinion on Investigational Drugs
Section Review: Cardiovascular & Renal: Novel antiplatelet agents: The glycoprotein IIb/IIIa inhibitors
Why the study?
Do glycoprotein IIb/IIIa inhibitors improve outcomes in patients with acute coronary syndromes or those undergoing percutaneous coronary intervention?
Population
Patients with cardiovascular disease states including acute coronary syndromes, myocardial infarction…
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
This review highlights the biological rationale and early clinical promise of glycoprotein IIb/IIIa inhibitors as potent antiplatelet agents for acute coronary syndromes and percutaneous coronary interventions.
Structured PICO
Do glycoprotein IIb/IIIa inhibitors improve outcomes in patients with acute coronary syndromes or those undergoing percutaneous coronary intervention?
P
Population
Patients with cardiovascular disease states including acute coronary syndromes, myocardial infarction, unstable angina, and those undergoing percutaneous transluminal coronary angioplasty (PTCA).
I
Intervention
Glycoprotein IIb/IIIa receptor inhibitors
This review highlights the biological rationale and early clinical promise of glycoprotein IIb/IIIa inhibitors as potent antiplatelet agents for acute coronary syndromes and percutaneous coronary interventions.
Cite This Study
Crenshaw et al. (1995) studied this question.